ES2912306T3 - Tetratiomolibdato de bis-colina para el tratamiento de enfermedad de Wilson - Google Patents

Tetratiomolibdato de bis-colina para el tratamiento de enfermedad de Wilson Download PDF

Info

Publication number
ES2912306T3
ES2912306T3 ES18815624T ES18815624T ES2912306T3 ES 2912306 T3 ES2912306 T3 ES 2912306T3 ES 18815624 T ES18815624 T ES 18815624T ES 18815624 T ES18815624 T ES 18815624T ES 2912306 T3 ES2912306 T3 ES 2912306T3
Authority
ES
Spain
Prior art keywords
bis
choline tetrathiomolybdate
patient
dose
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18815624T
Other languages
English (en)
Spanish (es)
Inventor
Aftab Ala
Carl Bjartmar
Karl-Heinz Weiss
Michael Schilsky
Frederick Askari
Anna Czlonkowska
Peter Ferenci
Peter Hedera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2912306T3 publication Critical patent/ES2912306T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES18815624T 2017-12-04 2018-12-04 Tetratiomolibdato de bis-colina para el tratamiento de enfermedad de Wilson Active ES2912306T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762594184P 2017-12-04 2017-12-04
US201862646553P 2018-03-22 2018-03-22
US201862655568P 2018-04-10 2018-04-10
US201862669095P 2018-05-09 2018-05-09
US201862741313P 2018-10-04 2018-10-04
US201862750595P 2018-10-25 2018-10-25
PCT/EP2018/083551 WO2019110619A1 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating wilson disease

Publications (1)

Publication Number Publication Date
ES2912306T3 true ES2912306T3 (es) 2022-05-25

Family

ID=64661349

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18815624T Active ES2912306T3 (es) 2017-12-04 2018-12-04 Tetratiomolibdato de bis-colina para el tratamiento de enfermedad de Wilson
ES21215264T Active ES3026756T3 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating wilson disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES21215264T Active ES3026756T3 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating wilson disease

Country Status (17)

Country Link
US (3) US11510944B2 (enExample)
EP (3) EP4029498B1 (enExample)
JP (3) JP2021505655A (enExample)
KR (1) KR102803161B1 (enExample)
AU (1) AU2018379255B2 (enExample)
BR (1) BR112020011055A2 (enExample)
CA (1) CA3084100A1 (enExample)
DK (2) DK3720433T3 (enExample)
ES (2) ES2912306T3 (enExample)
FI (1) FI4029498T3 (enExample)
HU (2) HUE071155T2 (enExample)
IL (1) IL275115B2 (enExample)
MX (1) MX2020006284A (enExample)
PL (2) PL3720433T3 (enExample)
PT (2) PT4029498T (enExample)
SI (2) SI3720433T1 (enExample)
WO (1) WO2019110619A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
AU2018379255B2 (en) 2017-12-04 2024-10-17 Alexion Pharma International Operations Unlimited Company Bis-choline tetrathiomolybdate for treating Wilson Disease
EP3749417A1 (en) 2018-02-06 2020-12-16 Alexion Pharma International Operations Unlimited Company Crystalline particles of bis-choline tetrathiomolybdate
JP2023502389A (ja) 2019-11-21 2023-01-24 アレクシオン ファーマシューティカルズ, インコーポレイテッド ウィルソン病患者における神経損傷を低下させるための方法
US20240044920A1 (en) * 2020-09-11 2024-02-08 Alexion Pharmaceuticals, Inc. Anti-ceruloplasmin antibodies and uses thereof
CA3172751A1 (en) * 2020-11-13 2022-05-19 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
JP2024505229A (ja) * 2021-01-31 2024-02-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 銅代謝関連疾患又は障害を治療するための新規製剤
JP2024532131A (ja) * 2021-08-17 2024-09-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 銅代謝関連疾患又は障害を治療する方法
AU2023427396A1 (en) 2023-01-30 2025-08-21 Alexion Pharmaceuticals, Inc. Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
EP1539131A4 (en) * 2002-07-23 2009-07-08 Univ Michigan TETRAPROPYLAMMONIUM TETRATHIOMOLYBDATE AND RELATED COMPOUNDS FOR ANTI-ANGIOGENOUS THERAPIES
AU2007205996A1 (en) * 2006-01-10 2007-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
AU2018379255B2 (en) 2017-12-04 2024-10-17 Alexion Pharma International Operations Unlimited Company Bis-choline tetrathiomolybdate for treating Wilson Disease
EP3749417A1 (en) 2018-02-06 2020-12-16 Alexion Pharma International Operations Unlimited Company Crystalline particles of bis-choline tetrathiomolybdate

Also Published As

Publication number Publication date
WO2019110619A1 (en) 2019-06-13
PL4029498T3 (pl) 2025-06-02
KR20200096798A (ko) 2020-08-13
CA3084100A1 (en) 2019-06-13
KR102803161B1 (ko) 2025-05-07
PL3720433T3 (pl) 2022-07-18
EP3720433A1 (en) 2020-10-14
EP4029498A1 (en) 2022-07-20
MX2020006284A (es) 2021-04-12
US20230070534A1 (en) 2023-03-09
JP2023075247A (ja) 2023-05-30
AU2018379255A1 (en) 2020-06-25
SI3720433T1 (sl) 2022-09-30
JP2021505655A (ja) 2021-02-18
DK4029498T3 (da) 2025-04-28
IL275115B1 (en) 2025-06-01
US20210177894A1 (en) 2021-06-17
US12233088B2 (en) 2025-02-25
US20210137972A1 (en) 2021-05-13
PT3720433T (pt) 2022-05-03
EP4029498B1 (en) 2025-02-05
HUE058921T2 (hu) 2022-09-28
US11510944B2 (en) 2022-11-29
IL275115A (en) 2020-07-30
EP3720433B1 (en) 2022-02-02
DK3720433T3 (da) 2022-05-02
EP4523745A3 (en) 2025-05-14
AU2018379255B2 (en) 2024-10-17
PT4029498T (pt) 2025-05-06
RU2020122023A (ru) 2022-01-10
SI4029498T1 (sl) 2025-07-31
EP4523745A2 (en) 2025-03-19
FI4029498T3 (fi) 2025-04-29
JP2025066802A (ja) 2025-04-23
ES3026756T3 (en) 2025-06-12
HUE071155T2 (hu) 2025-08-28
BR112020011055A2 (pt) 2020-11-17
IL275115B2 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
ES2912306T3 (es) Tetratiomolibdato de bis-colina para el tratamiento de enfermedad de Wilson
JP6612370B2 (ja) ポンペ病の処置のための投与計画
CN103974619B (zh) 治疗法布里病的给药方案
US11419832B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
PT2275086E (pt) Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
US11872204B1 (en) Methods of administering solriamfetol to lactating women
JP2025513844A (ja) アルギナーゼ1欠損症の処置
US20160128954A1 (en) Methods of Treating Huntington's Disease Using Cysteamine Compositions
US12064411B1 (en) Methods of administering solriamfetol to lactating women
RU2787632C2 (ru) Бис-холина тетратиомолибдат для лечения болезни вильсона
JP2022538210A (ja) 腎機能障害患者における高アンモニア血症の治療
US12263145B2 (en) Methods of administering solriamfetol to lactating women
WO2025235366A1 (en) Pyrrolopyrimidine compositions for treatment of atopic dermatitis
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途